Are there any new FDA approved pharmaceutical interventions or non invasive nerve stimulation devices for refractory restless legs syndrome that do not cause augmentation symptoms over time?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Are there any new FDA approved pharmaceutical interventions or non invasive nerve stimulation devices for refractory restless legs syndrome that do not cause augmentation symptoms over time?
2 real searches · 1 real-search pass
2026 FDA approved refractory restless legs syndrome new drugs noninvasive nerve stimulation device NTX100 Nidra FDA De Novo augmentation long term evidenceGoogle ↗
OBSERVED
AASM restless legs syndrome guideline 2025 augmentation gabapentin iron opioids dopamine agonists augmentation recommendationsGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 2 queries…
Searches and sources
ChatGPT2 real searches · gpt-6
2026 FDA approved refractory restless legs syndrome new drugs noninvasive nerve stimulation device NTX100 Nidra FDA De Novo augmentation long term evidence Google ↗
AASM restless legs syndrome guideline 2025 augmentation gabapentin iron opioids dopamine agonists augmentation recommendations Google ↗
- Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study · pubmed.ncbi.nlm.nih.gov
- Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study · pmc.ncbi.nlm.nih.gov
- Real-world effectiveness and safety of tonic motor activation therapy for refractory restless legs syndrome: 90-day outcomes from the THRIVE prospective observational study. · pubmed.ncbi.nlm.nih.gov
- Real-world effectiveness and safety of tonic motor activation therapy for refractory restless legs syndrome: 90-day outcomes from the THRIVE prospective observational study | SLEEP · academic.oup.com
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline · pmc.ncbi.nlm.nih.gov
- DailyMed - HORIZANT- gabapentin enacarbil tablet, extended release · dailymed.nlm.nih.gov
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline · irlssg.org
Queries
2 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2026 FDA approved refractory restless legs syndrome new drugs noninvasive nerve stimulation device NTX100 Nidra FDA De Novo augmentation long term evidence OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
AASM restless legs syndrome guideline 2025 augmentation gabapentin iron opioids dopamine agonists augmentation recommendations OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |